FY2025 EPS Estimates for BrainsWay Cut by HC Wainwright

BrainsWay Ltd. (NASDAQ:BWAY - Free Report) - Stock analysts at HC Wainwright reduced their FY2025 earnings per share estimates for shares of BrainsWay in a research note issued on Monday, October 21st. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.07 per share for the year, down from their previous estimate of $0.16. HC Wainwright has a "Buy" rating and a $16.00 price objective on the stock. The consensus estimate for BrainsWay's current full-year earnings is $0.06 per share.

BrainsWay (NASDAQ:BWAY - Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.04 EPS for the quarter. The firm had revenue of $10.01 million during the quarter, compared to analyst estimates of $9.40 million. BrainsWay had a net margin of 1.67% and a return on equity of 1.45%. During the same quarter last year, the business posted ($0.05) EPS.

Separately, Northland Securities increased their price target on shares of BrainsWay from $11.00 to $12.50 and gave the stock an "outperform" rating in a research report on Thursday, October 3rd.

BrainsWay Stock Performance

Shares of BWAY stock traded down $0.37 on Wednesday, reaching $9.55. 72,908 shares of the company's stock traded hands, compared to its average volume of 96,354. The business's 50 day moving average price is $8.47 and its two-hundred day moving average price is $6.90. The company has a market capitalization of $159.15 million, a P/E ratio of -110.22 and a beta of 1.26. BrainsWay has a 12-month low of $3.09 and a 12-month high of $10.61.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of BWAY. Rhumbline Advisers grew its stake in shares of BrainsWay by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 18,077 shares of the company's stock valued at $110,000 after buying an additional 1,695 shares in the last quarter. Quadrature Capital Ltd bought a new position in shares of BrainsWay during the 4th quarter valued at $70,000. Virtu Financial LLC bought a new position in shares of BrainsWay during the 1st quarter valued at $60,000. Perritt Capital Management Inc bought a new stake in BrainsWay in the second quarter worth $121,000. Finally, Good Life Advisors LLC increased its position in BrainsWay by 65.5% during the third quarter. Good Life Advisors LLC now owns 55,800 shares of the company's stock worth $516,000 after buying an additional 22,080 shares during the last quarter. 30.11% of the stock is owned by institutional investors and hedge funds.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.